Cumberland Pharmaceuticals Inc. — Q1 2012 Form 10-Q Summary
Business Context and Reporting Period
Unaudited quarterly report for the three months ended March 31, 2012. Cumberland is a specialty pharmaceutical company focused on hospital acute care and gastroenterology products, including Acetadote, Kristalose and Caldolor, with development activities including Hepatoren.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net revenues | $10.3 million | $10.7 million | Down 3.9% |
| Operating income | $0.6 million | $1.4 million | Down 54.1% |
| Net income attributable to common shareholders | $0.4 million | $0.7 million | Down 41.3% |
| Diluted EPS | $0.02 | $0.03 | Decreased |
| Net cash provided by operating activities | $2.6 million | $1.0 million | Increased |
| Cash and cash equivalents | $55.6 million | $66.0 million at March 31, 2011 | Decreased year over year |
Gross margin was approximately 91.7%, compared with 92.6% in Q1 2011. Operating margin was approximately 6.3%, compared with 13.2%, and net margin attributable to common shareholders was approximately 4.1%, compared with 6.8%.
At March 31, 2012, cash and marketable securities totaled $71.6 million, compared with $70.6 million at December 31, 2011. Working capital was $80.1 million and the current ratio was 14.0x. The company had $5.1 million outstanding under its revolving credit facility and approximately $4.9 million of additional availability. Total liabilities were $12.7 million, compared with total equity of $81.8 million.
Material Changes Versus the Prior Comparable Period
- Acetadote revenue declined approximately $1.2 million, primarily because of lower sales volume.
- Kristalose revenue increased approximately $0.2 million, and Caldolor revenue increased approximately $0.1 million, both primarily from higher volume.
- Other revenue increased to approximately $0.5 million from approximately $0.04 million, including approximately $0.5 million recognized under the China licensing agreement with Harbin Gloria Pharmaceuticals.
- Cost of products sold increased as a percentage of revenue to 8.3% from 7.4% because of product mix.
- Selling and marketing expense decreased approximately 6% to $5.0 million, while research and development expense increased approximately 39% to $1.4 million and general and administrative expense increased approximately 13% to approximately $2.3 million.
- Interest expense declined substantially to approximately $0.02 million from $0.2 million, primarily following repayment of the term debt facility in Q3 2011.
- The company repurchased 319,723 shares for approximately $2.3 million during the quarter, reducing shares outstanding to 19,870,637 at March 31, 2012.
Cash Flow, Investments and Liquidity
Operating cash flow was $2.6 million, aided substantially by a $2.6 million favorable change in accounts receivable. Investing activities used $16.2 million, primarily because the company invested $16.0 million in marketable securities. Financing activities used $1.4 million, principally for share repurchases, partially offset by stock-option proceeds and $0.25 million of net borrowings under the revolving credit facility.
Management stated that internally generated cash flow, available credit facilities and cash on hand are expected to be adequate to service existing debt, fund internal growth and finance capital expenditures. The company held approximately $2.1 million of inventory reserves, primarily related to Caldolor, because of potential obsolescence and discontinuance risk.
Guidance, Outlook, Commentary and Risks
- No formal revenue or earnings guidance was provided. Management expects research and development expenses to increase during 2012 as clinical study programs continue.
- The Harbin Gloria agreement grants exclusive Chinese commercialization rights for Acetadote and Caldolor. The company recognized approximately $0.5 million of the $0.7 million upfront payment; the remaining $0.2 million is deferred until Acetadote intellectual property is delivered. Additional potential milestone payments total $1.8 million, subject to specified regulatory events.
- The USPTO issued an Acetadote patent in April 2012, listed in the FDA Orange Book and scheduled to expire in May 2026. InnoPharma, Paddock Laboratories and Mylan Institutional issued Paragraph IV challenges alleging non-infringement and/or invalidity. The company had not filed infringement lawsuits as of the report date and was evaluating its options.
- Loss of Acetadote patent protection or generic competition could reduce sales and market share and require lower pricing or higher marketing expenditures. Caldolor also faces potential competition after expiration of its marketing exclusivity and from distinct competing formulations.
- The company reported approximately $57.8 million of net operating loss carryforwards from exercises of nonqualified options and expects minimal future cash income taxes as these benefits are used. The IRS was examining the company’s 2009 federal tax return, with completion expected during 2012.
- Marketable securities consisted of trading securities, including U.S. Treasury, government agency, mortgage-backed, SBA loan pool and municipal variable-rate demand note investments. Management reported no off-balance-sheet arrangements.
Important Facts for Investors to Verify
- Whether Acetadote sales stabilize and how the Paragraph IV patent challenges affect commercialization and legal costs.
- The timing and collectability of deferred and potential milestone revenue under the Harbin Gloria agreement.
- Cal dolor inventory levels, expiration dates and the adequacy of the approximately $2.1 million obsolescence reserve.
- Whether higher research and development and administrative spending produces meaningful development or commercial progress.
- The company’s continued share repurchases, revolving-credit borrowings and allocation of cash to marketable securities.
- Results and potential tax effects of the IRS examination of the 2009 federal tax return.